[The effectiveness of short and prolonged course treatment of anxiety with Anvifen]. / Effektivnost' korotkogo i prolongirovannogo kursovogo lecheniya trevozhnogo rasstroistva preparatom Anvifen.

OBJECTIVE: To determine the effectiveness of the treatment of anxiety disorder with Anvifen (aminophenylbutyric acid) in a short (21 days) and prolonged (60 days) course of treatment. MATERIAL AND METHODS: Patients were randomly divided into two groups: a short course (21 days) of treatment with Anvifen (group 1) and a prolonged course (60 days) of treatment with Avifen (group 2). In each group, patients were divided into age subgroups: 20-40 years old (1a - n=30, mean age 32 [21; 39], 2a - n=30, mean age 33 [23; 38] years) and 41-70 years (1b - n=30, mean age 62 [51; 67] years; 2b - n=30, mean age 60 [51; 68] years). Evaluated by: Hospital Anxiety and Depression Scale (HADS); fatigue according to the Russian version of the fatigue assessment scale (The Fatigue Assessment Scale - FAS); sleep assessment according to the questionnaire for scoring the subjective characteristics of sleep (sleep assessment - OS); mean frequency per month of attacks meeting the criteria for a panic attack (PA) in the previous 6 months; a comprehensive assessment of the severity of all subjective symptoms on a 10-point numerical rank scale (NRS), where «0¼ corresponded to the complete absence of any significant subjective symptoms, «10¼ - the maximum degree of bodily and mental discomfort presented by the patient. Anvifen patients took at a dose of 500 mg three times a day. The evaluation of the studied parameters was carried out at the point «1¼ (before the start of treatment), at point «2¼ at the end of the course of treatment (for group 1 - on the 21st day of treatment, for group 2 - on the 60th day of treatment), at point «3¼ (30 days after the end of treatment for patients in both groups). RESULTS: The indicators of subgroups 1a and 1b at point 2 had a significant positive trend (p<0.05) compared with the indicators at point 1, but at point 3 these indicators did not differ significantly (p>0.05). The indicators of subgroups 2a and 2b at point 2 had a significant positive trend (p<0.05) compared with the indicators at point 1, and these differences persisted at point 3 (p<0.05). CONCLUSION: Anvifen effectively eliminates anxiety symptoms, but the effect of a short course lasts less than 1 month, the effect of prolonged treatment lasts more than 1 month. The authors recommend prolonged treatment of anxiety with Anvifen for at least 2 months.

[Effectiveness of the anxiolytic Anvifen in the treatment of post-COVID brain fog]. / Effektivnost' preparata Anvifen pri lechenii patsientov s sindromom postkovidnogo «tumana v golove¼.

OBJECTIVE: To determine the significance of anxiety disorder and comorbid disorders in patients with post-covid brain fog, to determine the effectiveness of the GABAergic nootropic drug with an anxiolytic effect - Anvifen. MATERIAL AND METHODS: 92 post-COVID-19 patients with no organic brain damage who complain of brain fog 12 weeks after the onset of COVID-19 symptoms. Group 1 (n=40; 43.4±4.5 years) were treated at home; group 2 (n=32; 44.9±5.5 years) were treated in a hospital without oxygen support; group 3 (n=20; 45.1±4.8 years) were treated in a hospital with oxygen support. Assessment scales: Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment Scale (MoCA); Trail Making Test part B (TMT-B); a scoring questionnaire for the subjective characteristics of sleep; Fatigue Assessment Scale (FAS), 36-Item Short Form Survey (SF-36). According to the indicated scales, no statistically significant differences were found between the groups, therefore, the data of all patients were combined into one group, the indicators were compared before and after treatment (Anvifen 500 mg three times a day for 21 days). RESULTS: Results before/after treatment: HADS anxiety 10.5 [8.5;12]/7 [5;8] (p=0.000025); HADS depression 5 [4; 7] / 4 [4; 6] (p=0.00003); MoCA 22 [21; 22] / 25 [24; 26] (p=0.00001); TMT-B 281 [279; 290] sec / 231 [220; 236] sec (p=0.00001); FAS 27 [23; 31] / 20 [23; 31] (p=0.00001); questionnaire for scoring the subjective characteristics of sleep 15 [15; 16] / 25 [25; 26] (p=0.00001); SF-36 Physical Health 43.8 [42.3; 47.4] / 53.8 [52.3; 20] (p=0.00001); SF-36 Mental Health 34 [32.5; 35] / 47 [45.5; 48] (p=0.00001). CONCLUSION: The authors conclude that anxiety disorder and asthenia play an important role in the pathogenesis of post-COVID brain fog syndrome. Anvifen effectiveness is considered from the point of view of the participation of GABAergic structures in the pathogenesis of the phenomenon under study.